Cost-benefit of vaccination against influenza in children under 5 years of age: systematic review
Abstract
The influenza is a contagious respiratory pathology that affects the nose, throat and in certain cases the lungs. Vaccination is one of the most effective ways to prevent it. For this reason, the objective was to analize the cost-benefit of vaccination against influenza. A systematic review of the influenza vaccines published during the last 10 years was carried out using databases such as Pubmed, Science Direct, Scielo, Scopus, through DeCS and MesH search terms, also using Boolean operators AND. 15 articles met the inclusion criteria. According to the results, influenza immunization brings cost savings from the perspective of the payer and society, and avoids medical consultations, hospitalizations, and deaths in vulnerable groups. Concluding that influenza immunization is an effective and economical method for people and countries since it avoids medical costs.Downloads
References
Programa ampliado de inmunizaciones. Ministerio de Salud Pública Dirección de Nacional de Estrategias de Salud Colectiva Programa Ampliado de Inmunizaciones Lineamientos Campaña De Vacunación Contra Influenza Estacional del 5 al 30 de noviembre 2012. 2012;1–15.
Llamas R. The role of the influenza vaccine and its impact in Cardiology. Vol. 27, Revista Colombiana de Cardiologia. 2020. p. 582–8.
Sosa A, Sosa M, Zaidel E, Aisenberg G, Barachuk G, Costa E, Borrayo G, Fernando B, Lopez R, Munera A, Perel P, Piskorz D, Ruiz C, Saucedo J, Valdez O, González J. Vacunación contra Influenza para la Prevención de la Enfermedad Cardiovascular en las Américas. 2020.
Hernández C, Férnandez R, Aguiar E. Revisión integrativa sobre la pertinencia de las vacunas VPH, influenza y dengue para la salud pública en México. Univ Autónoma Nayarit. 2017;10(2231):123–89.
Loayza S. Costo-utilidad de la introducción de la vacuna inactivada contra la influenza cuadrivalente al programa de inmunizaciones de Chile: análisis en grupos de 6 meses a 5 años y ≥ 65 años. Sarinet. 2017;
Pérez-Rubio A, Castrodeza J, Eiros J. Choice of influenza vaccine in people over 65 years old. Analysis of reports from international vaccination advisory committees. Rev Esp Quimioter. 2021;34(6):631–8.
Gobierno de Colombia. Ministerio de Salud y Protección Social. Lineamientos para la vacunación contra la influenza estacional - Cepa Sur 2021. 2021. p. 22.
Lucia S, Lafranconi A, Cortesi P, Rota S, Giancarlo L. Costs and effectiveness of influenza vaccination: a systematic review. Ann Ist Super Sanità. 2018;54(1):49–57.
Sotomayor J, Sánchez X, Vilema M, Ghisays G. Cost of routine immunisation of infants less than one year-old in Ecuador. Vacunas. 2018;19(2):61–6.
Amaya N, Andrea P, Romero T. Metodología del análisis de costo-efectividad (ACE) en la práctica clínica Methodology of Cost-effectiveness Analysis in Clinic Practice Metodologia de análise de custo-efetividade em prática clínica. Investig en Segur Soc y Salud. 2015;17(1):67–76.
Martínez-Betancur O, Quintero-Cusguen P, Mayor-Agredo L. Estimating disability-adjusted life-years for subtypes of acute ischemic stroke. Rev Salud Publica (Bogota). 2016;18(2):226–37.
Valcárcel N, García-Lorenzo B, Del-Pino T, García-Pérez L, Brito-García N, Linertová R, et al. Coste-efectividad de la vacunación contra la gripe estacional para diferentes grupos de edad: Una revisión sistemática. Rev Esp Salud Publica. 2018;92.
Critical Appraisal Skills Program. CASP-Systematic Review. 2018;
Basurto-Dávila R, Meltzer M, Mills D, Beeler-Asay G, Cho B, Graitcer S, et al. School-Based Influenza Vaccination: Health and Economic Impact of Maine’s 2009 Influenza Vaccination Program. Health Serv Res. 2017;52:2307–30.
Bellier L, Petitjean A, Sarazu T, Tresierra J, Lopez J. Cost-effectiveness analysis of switching from a trivalent to a quadrivalent inactivated influenza vaccine in the Peruvian immunisation programme. Vaccine. 2021;39(30):4144–52.
Bianculli P, Bellier L, Mangado I, Pérez C, Mieres G, Lazarov L, et al. Switching from trivalent to quadrivalent inactivated influenza vaccines in Uruguay: a cost-effectiveness analysis. Hum Vaccines Immunother. 2022;18(5).
Brogan A, Talbird S, Davis A, Thommes E, Meier G. Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: A dynamic transmission modeling approach. Hum Vaccines Immunother. 2017;13(3):533–42.
Crépey P, Boiron L, Araujo R, Lopez J, Petitjean A, de-Albuquerque L. Impact of quadrivalent influenza vaccines in Brazil: A cost-effectiveness analysis using an influenza transmission model. BMC Public Health. 2020;20(1):1–11.
De-Waure C, Veneziano M, Cadeddu C, Capizzi S, Specchia M, Capri S, et al. Economic value of influenza vaccination. Hum Vaccines Immunother. 2012;8(1):119–29.
Giglio N, Gentile A, Lees L, Micone P, Armoni J, Reygrobellet C, et al. Public health and economic benefits of new pediatric influenza vaccination programs in Argentina. Hum Vaccin Immunother. 2012;8(3):312–22.
Gregg M, Blackhouse G, Loeb M, Goeree R. Economic evaluation of an influenza immunization strategy of healthy children. Int J Technol Assess Health Care. 2014;30(4):394–9.
Jamotte A, Clay E, Macabeo B, Caicedo A, Lopez J, Bricks L, et al. Public health impact and economic benefits of quadrivalent influenza vaccine in Latin America. Hum Vaccines Immunother. 2017;13(4):877–88.
Lara C, De-Graeve D, Franco F. Cost-Effectiveness Analysis of Pneumococcal and Influenza Vaccines Administered to Children Less Than 5 Years of Age in a Low-Income District of Bogota, Colombia. Value Heal Reg Issues. 2018;17:21–31.
Ruiz-Palacios G, Beigel J, Guerrero M, Bellier L, Tamayo R, Cervantes P, et al. Public health and economic impact of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Mexico. Hum Vaccines Immunother. 2020;16(4):827–35.
Thommes E, Ismaila A, Chit A, Meier G, Bauch C. Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: A dynamic modeling study of Canada and the United Kingdom. BMC Infect Dis. 2015;15(1):1–14.
Thommes E, Kruse M, Kohli M, Sharma R, Noorduyn S. Review of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines. Vol. 13, Human Vaccines and Immunotherapeutics. 2017. p. 867–76.
Urueña A, Micone P, Magneres C, Mould-Quevedo J, Giglio N. Cost-effectiveness analysis of switching from trivalent to quadrivalent seasonal influenza vaccine in Argentina. Vaccines. 2021;9(4):1–14.
Salleras L, Navas E, Torner N, Prat A, Garrido P, Soldevila N, et al. Economic benefits of inactivated influenza vaccines in the prevention of seasonal influenza in children. Hum Vaccines Immunother. 2013;9(3):707–11.
Falcón-Lezama J, Saucedo-Martínez R, Betancourt-Cravioto M, Alfaro-Cortes M, Bahena-González R, Tapia-Conyer R. Influenza in the school-aged population in Mexico: Burden of disease and cost-effectiveness of vaccination in children. BMC Infect Dis. 2020;20(1):1–17.
Yoo B, Schaffer S, Humiston S, Rand C, Goldstein N, Albertin C, et al. Cost effectiveness of school-located influenza vaccination programs for elementary and secondary school children. BMC Health Serv Res. 2019;19(1):1–12.
Shim E, Brown S, DePasse J, Nowalk M, Raviotta J, Smith K, et al. Cost Effectiveness of Influenza Vaccine for U.S. Children: Live Attenuated and Inactivated Influenza Vaccine. Am J Prev Med. 2016;51(3):309–17.
Newall A, Jit M, Beutels P. Economic evaluations of childhood influenza vaccination: A critical review. Pharmacoeconomics. 2012;30(8):647–60.
DePasse J, Nowalk M, Smith K, Raviotta J, Shim E, Zimmerman R, et al. Does cost-effectiveness of influenza vaccine choice vary across the U.S.? An agent-based modeling study. Vaccine. 2017;35(32):3974–81.
Hart R, Stevenson M, Smith M, Scott L, Cross K. Cost-effectiveness of strategies for offering influenza vaccine in the pediatric emergency department. JAMA Pediatr. 2018;172(1):1–9.
de Boer P, van Maanen B, Damm O, Ultsch B, Dolk F, Crépey P, et al. A systematic review of the health economic consequences of quadrivalent influenza vaccination. Expert Rev Pharmacoeconomics Outcomes Res. 2017;17(3):249–65.
Ting E, Sander B, Ungar W. Systematic review of the cost-effectiveness of influenza immunization programs. Vaccine. 2017;35(15):1828–43.
Copyright (c) 2023 FACSALUD-UNEMI
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Todos los artículos de la Revista FACSalud UNEMI son difundidos bajo licencia internacional Creative Commons Reconocimiento-NoComercial-SinObrasDerivadas 4.0.
Los autores mantienen los derechos de autor, y, por lo tanto, son libres de compartir, copiar, distribuir, ejecutar y comunicar públicamente la obra bajo las condiciones siguientes: Reconocer los créditos de la obra especificada por el autor e indicar si se realizaron cambios (puede hacerlo de cualquier forma razonable, pero no de una manera que sugiera que el autor respalda el uso que hace de su obra. No utilizar la obra para fines comerciales. En caso de remezcla, transformación o desarrollo, no puede distribuirse el material modificado.
